3 hours UBS Group Begins Coverage on Blueprint Medicines (NASDAQ:BPMC)MarketBeat
UBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday. They set a “neutral” rating and a $88.00 price target for the company.
XUBS Group started coverage on shares of Blueprint Medicines in a research note on Thursday. They set a “neutral” rating and a $88.00 price target for the company.
X